Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2016 /
ASCEND-5: Ceritinib for ALK positive NSCLC previously treated with crizotinib

7th - 11th Oct 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.10.16
Views: 3283

Dr Giorgio Scagliotti - University of Turin, Turin, Italy

Dr Scagliotti speaks to ecancertv at ESMO 2016 about results from the confirmatory phase III trial ASCEND-5.

He summarises these results, confirming the benefit of ceritinib for lung cancer patients with ALK rearrangements who had previously received crizotinib, and goes on to consider the impact of kinase inhibitor therapy.

Video of the press conference in which these results were announced is available here.

ecancer's filming at ESMO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation